Build status - In Progress

Evaluating the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis.

Recruiting
18 years - 50 years
Female
Phase 3
1020 participants needed
1 Location

Brief description of study

This study is intended to demonstrate the contraceptive efficacy of relugolix combination therapy. Myovant is developing relugolix combination therapy for the indications of the management of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Uterine Fibroids, Endometriosis
  • Age: 18 years - 50 years
  • Gender: Female

Women, Ages 18 to 50

Updated on 04 Aug 2024. Study ID: 850525

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center